A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-01-29
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 167); relationship: not assessed
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 212); relationship: not assessed
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-16 (study day 244); relationship: not assessed
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-07-29 (study day 531); relationship: not assessed
Data queries
No data queries.